FDA is the world’s largest healthcare agency of USA and is responsible for the development of Science all over the world. It is imperative by the fact that simply a rejection of manufacturing Unit of a company can lead to severe loss on stock exchanges all over the world.
But here we are discussing about the quick exit of FDA Chief Dr Scott Gottlieb(46) which is a reaction of several actions that he took and more to some personal reasons here which he think is the priority for him at this time.
According to latest reports by Time, CNN, Fortunately he is finally resigning from the post and seen as a good sign for the hounded growth of Tobacco industry.
Dr. Scott Gottlieb said in a letter to staff Tuesday that he will be leaving the agency.
“It’s is hard for me to write this note to share with you the news that I’ll be leaving my job as the Commissioner of Food and Drugs in the next month. There’s perhaps nothing that could pull me away from this role other than the challenge of being apart from my family for these past two years and missing my wife and three young children,” says the letter, which the FDA tweeted.
Dr Gottlieb is facing serious difficulty after his move on banning cigarettes even to replace them by e-cigarettes and Teen vaping. As head of the FDA, Gottlieb made crack down on e-cigarettes and vaping as a key part of his tenure. During his tenure as commissioner, Gottlieb approved a record number of treatments and drugs and advanced policies to confront opioid addiction and prevent youth e-cigarette use. He also faced the longest government shutdown in history. He has been particularly aggressive on the issue of e-cigarette use, targeting convenience stores that sell vaping products, aiming to limit the access and appeal these products have for children.
Move of Dr Gottlieb can affect many industries in the market, specially the pharmaceutical and medical device business. The one category is Biologics and biosimilars which he developed a lot in his regime. According to many he has approved record biosimilars in the market, and that is why the biologics drug manufacturers are looking forward curiously for the coming administration.
Alex Azar, secretary of the Department of Health and Human Services, the FDA’s parent agency, said in a statement Tuesday that Gottlieb “has been an exemplary public health leader, aggressive advocate for American patients, and passionate promoter of innovation.”
USA President Donald Trump also tweeted about Gottlieb’s planned departure, saying he’s done a “absolutely terrific job.”
“Scott has helped us to lower drug prices, get a record number of generic drugs approved and onto the market, and so many other things. He and his talents will be greatly missed!”
Dr Gottlieb previously worked as a senior adviser to the Centers for Medicare and Medicaid Services and was appointed by the Senate to serve on the Federal Health Information Technology Policy Committee.
Before these appointments, he served as a clinical assistant professor at the New York University School of Medicine in Manhattan, where he also practiced medicine as a hospitalist physician.
He completed a residency in internal medicine at the Mount Sinai Medical Center in New York and is a graduate of the Mount Sinai School of Medicine and of Wesleyan University in Connecticut, where he studied economics.
Dr Gottlieb is also a cancer survivor, a venture capitalist and a government insider who long said he wanted to tear down the wall of FDA regulations that he believes is holding back innovation.
Not everyone is praising Dr Gottlieb’s tenure. The advocacy group Public Citizen said in a statement Tuesday that his time as the agency’s head “was marked by regulatory decision making regarding medications and medical devices that tilted further in favor of industry’s financial interests rather than the interests of public health.”
